Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$155.55M+10.9%$140.33M+5.5%$132.96M+9.5%$121.43M+11.9%$108.47M+12.5%
$40.91M+5.2%$38.88M+5.8%$36.74M+3.8%$35.4M+2.8%$34.45M+3.5%
$196.46M+9.6%$179.21M+5.6%$169.7M+8.2%$156.82M+9.7%$142.92M+10.2%
-$196.46M-9.6%-$179.21M-5.6%-$169.7M-8.2%-$156.82M-9.7%-$142.92M-10.2%
-$208K-56.4%-$133K-147%$285K-8.9%$313K-7.9%
$5.07M-3.8%$5.27M
-$191.78M-10.0%-$174.33M-4.3%-$167.14M-8.5%-$154.08M-10.3%-$139.68M-12.0%
-$1.95+3.5%-$2.02+19.5%-$2.51+11.0%-$2.82+6.3%-$3.01+1.6%
-$194.84M-9.7%-$177.57M-5.7%-$168.04M-8.3%-$155.14M-10.5%-$140.38M-10.3%
-$196.46M-9.6%-$179.21M-5.6%-$169.7M-8.2%-$156.82M-9.7%-$142.92M-10.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Solid Biosciences Inc.'s revenue?
Solid Biosciences Inc. (SLDB) generated $8.1M in revenue over the trailing twelve months, down 40.6% year over year.
Is Solid Biosciences Inc. profitable?
Solid Biosciences Inc. is not currently profitable: it reported a net loss of $191.8M over the trailing twelve months, a -1062.3% net margin.
What is Solid Biosciences Inc.'s earnings per share?
Solid Biosciences Inc.'s diluted EPS over the trailing twelve months is $-1.95.
Where does Solid Biosciences Inc.'s income statement data come from?
Every line is extracted from Solid Biosciences Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.